Compare OXSQ & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | LFCR |
|---|---|---|
| Founded | 2003 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.9M | 190.9M |
| IPO Year | N/A | 1996 |
| Metric | OXSQ | LFCR |
|---|---|---|
| Price | $1.44 | $4.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.4M | 214.5K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 22.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $557,559,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | $5.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $1.05 | $3.63 |
| 52 Week High | $2.42 | $8.98 |
| Indicator | OXSQ | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 33.62 |
| Support Level | $1.26 | $4.22 |
| Resistance Level | $1.95 | $5.34 |
| Average True Range (ATR) | 0.06 | 0.29 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 18.18 | 3.06 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize portfolio's total return. Its primary current focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and, to a lesser extent collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. CLO investments may also include warehouse facilities, which are early-stage CLO vehicles intended to aggregate loans that may be used to form the basis of a traditional CLO vehicle. The company may also invest in publicly traded debt and/or equity securities.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.